سعر نيستاكوران 2مجم 20 قرص 2025

Nestacoran 2 mg film-coated tablets (Hi-pharm, Egypt): eszopiclone hypnotic for insomnia; pack of 20 tablets.

• Treatment of insomnia; in controlled trials it decreased sleep latency and improved sleep maintenance.Population: AdultsDailyMed (NLM)

• Most common (incidence 2% or more): unpleasant taste, headache, somnolence, respiratory infection, dizziness, dry mouth, rash, anxiety, hallucinations and viral infections; unpleasant taste is clearly dose-related.International label, same formulation · DailyMed (NLM)

• Patients who have experienced complex sleep behaviours after taking eszopiclone.International label, same formulation · DailyMed (NLM)
• Known hypersensitivity to eszopiclone (anaphylaxis and angioedema have been reported).International label, same formulation · DailyMed (NLM)

• Boxed warning: complex sleep behaviours including sleep-walking, sleep-driving and other activities while not fully awake may occur, sometimes causing serious injury or death; discontinue immediately if one occurs.International label, same formulation · DailyMed (NLM)
• CNS depressant effects and next-day impairment: risk increases with dose and with other CNS depressants (including alcohol); patients taking 3 mg should not drive or do activities requiring full alertness the next day.International label, same formulation · DailyMed (NLM)
• Evaluate for comorbid psychiatric or medical illness if insomnia persists after 7-10 days; abnormal thinking, behaviour changes, worsening depression and suicidal thoughts have been reported; withdrawal symptoms may follow rapid dose decrease or abrupt discontinuation.International label, same formulation · DailyMed (NLM)

• CNS depressants including alcoholAdditive CNS depression and psychomotor impairment (shown with ethanol); dose adjustment may be needed.DailyMed (NLM)
• OlanzapineCoadministration decreased DSST scores (pharmacodynamic interaction, no pharmacokinetic change).DailyMed (NLM)
• Potent CYP3A4 inhibitors (e.g. ketoconazole)Increase eszopiclone exposure and effect; do not exceed 2 mg.DailyMed (NLM)

• Available pharmacovigilance data in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or adverse outcomes; no teratogenicity in rats and rabbits, but offspring toxicities occurred when given throughout pregnancy and lactation in rats at about 200 times the maximum recommended human dose.International label, same formulation · DailyMed (NLM)
• No data on presence in human or animal milk or effects on the breastfed infant or milk production; weigh breastfeeding benefits against the mother's need and potential infant effects.International label, same formulation · DailyMed (NLM)